United States · FDA National Drug Code directory
Arcalyst
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 73604-914_11e22c54-9b9a-4f9f-8680-cb7327511a23
- Product NDC
- 73604-914
- Form
- INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
- Composition / generic term
- rilonacept
- Labeler
- Kiniksa Pharmaceuticals (UK), Ltd.
- Marketing category
- BLA
- Marketing start / end (source format)
- 20080227
- Source listing expiry
- 20261231
Source-listed ingredients
- RILONACEPT — 160 mg/2mL
These values do not establish equivalence or a dose recommendation.
Packages
- 1 VIAL, SINGLE-USE in 1 CARTON (73604-914-01) / 2 mL in 1 VIAL, SINGLE-USE · 73604-914-01
- 4 VIAL, SINGLE-USE in 1 CARTON (73604-914-04) / 2 mL in 1 VIAL, SINGLE-USE · 73604-914-04
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →